GSK Investigational Site

Namur 5101

2 studies enrolling now · 11 studies all time

What they study most

Asthma, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Carcinoma of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Lung Cancer, Non-Small Cell, Lung Diseases, Interstitial, Neoplasms, Breast, Ovarian Neoplasms, Pulmonary Disease, Chronic Obstructive, Respiratory Syncytial Virus Infections, Thrombocytopaenia

Studies at this site

• Depemokimab Asthma Imaging and Bronchoscopy Sub-Study — Recruiting now
• A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease — Recruiting now
• A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy — Running, not enrolling
• Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults — Completed
• A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients — Stopped early
• Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer — Stopped early
• GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer — Stopped early
• Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease — Completed
• Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag — Completed
• Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer — Stopped early